Molekulare Pathologie des kolorektalen Karzinoms
作者： J.H.L. Neumann , A. Jung , T. Kirchner
DOI: 10.1007/S00292-015-0005-3
关键词: DNA Mutational Analysis 、 Context (language use) 、 Oncology 、 Internal medicine 、 Microsatellite 、 Colorectal cancer 、 Mutational status 、 Who classification 、 In patient 、 Medicine 、 Microsatellite instability
摘要: In recent years, several predictive and prognostic biomarkers have been established in colorectal cancer (CRC). The RAS-mutation status is widely applied the daily routine diagnostic as biomarker for treatment with EGFR-inhibitors. A BRAF- mutation has no value this context. detection of high-grade microsatellite instability (MSI-H) a response to 5-Fluoruracil-monotherapy. Prognostic CRC are MSI-status mutational BRAF. According current WHO classification poorly undifferentiated MSI-associated special morphological subtypes molecular graded depending on their MSI-status. BRAF-mutation context stability (MSS) associated very poor prognosis thus represents most aggressive subtype CRC. patients positive Bethesda criteria stepwise immunohistochemical scheme proposed.
springer.com
sci-hub.se 参考文章(57)
M.J. Sorich, M.D. Wiese, A. Rowland, G. Kichenadasse, R.A. McKinnon, C.S. Karapetis, Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials Annals of Oncology. ,vol. 26, pp. 13- 21 ,(2015) , 10.1093/ANNONC/MDU378
Christopher W Toon, Angela Chou, Keshani DeSilva, Joseph Chan, Jillian Patterson, Adele Clarkson, Loretta Sioson, Lucy Jankova, Anthony J Gill, BRAFV600E immunohistochemistry in conjunction with mismatch repair status predicts survival in patients with colorectal cancer. Modern Pathology. ,vol. 27, pp. 644- 650 ,(2014) , 10.1038/MODPATHOL.2013.200
Harry H. Yoon, David Tougeron, Qian Shi, Steven R. Alberts, Michelle R. Mahoney, Garth D. Nelson, Suresh G. Nair, Stephen N. Thibodeau, Richard M. Goldberg, Daniel J. Sargent, Frank A. Sinicrope, , KRAS Codon 12 and 13 Mutations in Relation to Disease-Free Survival in BRAF–Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance) Clinical Cancer Research. ,vol. 20, pp. 3033- 3043 ,(2014) , 10.1158/1078-0432.CCR-13-3140
Christine M. Ribic, Daniel J. Sargent, Malcolm J. Moore, Stephen N. Thibodeau, Amy J. French, Richard M. Goldberg, Stanley R. Hamilton, Pierre Laurent-Puig, Robert Gryfe, Lois E. Shepherd, Dongsheng Tu, Mark Redston, Steven Gallinger, Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer The New England Journal of Medicine. ,vol. 349, pp. 247- 257 ,(2003) , 10.1056/NEJMOA022289
A. Umar, C. R. Boland, J. P. Terdiman, S. Syngal, A. d. l. Chapelle, J. Ruschoff, R. Fishel, N. M. Lindor, L. J. Burgart, R. Hamelin, S. R. Hamilton, R. A. Hiatt, J. Jass, A. Lindblom, H. T. Lynch, P. Peltomaki, S. D. Ramsey, M. A. Rodriguez-Bigas, H. F. A. Vasen, E. T. Hawk, J. C. Barrett, A. N. Freedman, S. Srivastava, Revised Bethesda Guidelines for Hereditary Nonpolyposis Colorectal Cancer (Lynch Syndrome) and Microsatellite Instability Journal of the National Cancer Institute. ,vol. 96, pp. 261- 268 ,(2004) , 10.1093/JNCI/DJH034
C. M. Wright, O. F. Dent, M. Barker, R. C. Newland, P. H. Chapuis, E. L. Bokey, J. P. Young, B. A. Leggett, J. R. Jass, G. A. Macdonald, Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer. British Journal of Surgery. ,vol. 87, pp. 1197- 1202 ,(2002) , 10.1046/J.1365-2168.2000.01508.X
John M. Carethers, Dharam P. Chauhan, Daniel Fink, Sibylle Nebel, Robert S. Bresalier, Stephen B. Howell, C.Richard Boland, Mismatch repair proficiency and in vitro response to 5-fluorouracil Gastroenterology. ,vol. 117, pp. 123- 131 ,(1999) , 10.1016/S0016-5085(99)70558-5
Wendy De Roock, Veerle De Vriendt, Nicola Normanno, Fortunato Ciardiello, Sabine Tejpar, KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer Lancet Oncology. ,vol. 12, pp. 594- 603 ,(2011) , 10.1016/S1470-2045(10)70209-6
Estefanía Rojas, Nuria Acame, Francisco J. Gutiérrez-Aviñó, Antoni Castells, Xavier Llor, Montserrat Andreu, José-Luis Soto, Rodrigo Jover, Lucía Pérez-Carbonell, Cristina Alenda, Artemio Payá, Adela Castillejo, Víctor M. Barberá, Carmen Guillén, Methylation Analysis of MLH1 Improves the Selection of Patients for Genetic Testing in Lynch Syndrome The Journal of Molecular Diagnostics. ,vol. 12, pp. 498- 504 ,(2010) , 10.2353/JMOLDX.2010.090212
Wendy De Roock, Bart Claes, David Bernasconi, Jef De Schutter, Bart Biesmans, George Fountzilas, Konstantine T Kalogeras, Vassiliki Kotoula, Demetris Papamichael, Pierre Laurent-Puig, Frédérique Penault-Llorca, Philippe Rougier, Bruno Vincenzi, Daniele Santini, Giuseppe Tonini, Federico Cappuzzo, Milo Frattini, Francesca Molinari, Piercarlo Saletti, Sara De Dosso, Miriam Martini, Alberto Bardelli, Salvatore Siena, Andrea Sartore-Bianchi, Josep Tabernero, Teresa Macarulla, Frédéric Di Fiore, Alice Oden Gangloff, Fortunato Ciardiello, Per Pfeiffer, Camilla Qvortrup, Tine Plato Hansen, Eric Van Cutsem, Hubert Piessevaux, Diether Lambrechts, Mauro Delorenzi, Sabine Tejpar, None, Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis Lancet Oncology. ,vol. 11, pp. 753- 762 ,(2010) , 10.1016/S1470-2045(10)70130-3